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Abstract
Introduction: The purpose of this study was to determine the prevalence of KAL1, GNRH1, GNRHR, PROK2, and PROKR2 copy number 
variations in patients with idiopathic hypogonadotropic hypogonadism (IHH). 
Material and methods: 86 hypogonadal males (76 diagnosed with normosmic idiopathic hypogonadotropic hypogonadism [nIHH] and 
ten with Kallmann syndrome [KS]) and 95 healthy control individuals were studied for the presence of aforementioned genomic rear-
rangements, using multiplex ligation dependent probe amplification (MLPA). 
Results: We detected that of the 86 patients, three with KS had a deletion of the KAL1 gene in exon 9, one of whom also carried a dupli-
cation in exon 11; and three with nIHH had a duplication of the PROK2 gene in exon 3; a deletion of the GNRHR gene in exon 1; and 
a duplication of the same gene in exon 2, respectively. No abnormalities were found in the patient group for the PROKR2 and GNRH1 
genes. In addition, no genomic rearrangements were identified in the healthy control individuals for the described genes. 
Conclusions: Defining the genetic basis of disease is essential to improve our understanding of this complex disorder, and could be use-
ful for genetic counselling and for directing therapy. In addition, discovering the association between genetic mutations and disease is 
important for our better understanding of normal reproductive functions. (Endokrynol Pol 2013; 64 (4): 285–292)
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Streszczenie
Wstęp: Celem badania było ustalenie rozpowszechnienia zmienności liczby kopii genów KAL1, GNRH1, GNRHR, PROK2 i PROKR2 
u pacjentów z idiopatycznym hipogonadyzmem hipogonadotropowym (IHH, idiopathic hypogonadotropic hypogonadism). 
Materiał i metody: Obecność wymienionych wyżej rearanżacji genomowych zbadano metodą zależnej od ligacji multipleksowej am-
plifikacji sond (MLPA, multiplex ligation dependent probe amplification) u 86 mężczyzn z hipogonadyzmem — w tym u 76 z rozpoznaniem 
IHH przebiegającego bez zaburzeń węchu (nIHH, normosmic idiopathic hypogonadotropic hypogonadism) i u 10 z rozpoznaniem zespołu 
Kallmanna (KS, Kallmann syndrome) — oraz u 95 zdrowych osobników kontrolnych. 
Wyniki: U 3 pacjentów z KS stwierdzono delecję w obrębie genu KAL1 w egzonie 9, przy czym u jednego z nich występowała też dupli-
kacja w egzonie 11. Z kolei łącznie u 3 pacjentów z nIHH stwierdzono: duplikację w obrębie genu PROK2 w egzonie 3 u jednego pacjenta, 
delecję w obrębie genu GNRHR w egzonie 1 u drugiego pacjenta oraz duplikację  obrębie tego samego genu w egzonie 2. Jeśli zaś chodzi o 
geny PROKR2 i GNRH1, to w grupie pacjentów nie stwierdzono żadnych nieprawidłowości w tym zakresie. Nie stwierdzono też żadnych 
rearanżacji genomowych w zakresie wymienionych genów u zdrowych osobników kontrolnych.
Wnioski: Określanie podłoża genetycznego ma ogromne znaczenie dla pogłębiania wiedzy na temat tej złożonej choroby i może 
być przydatne w poradnictwie genetycznym i ustalaniu leczenia. Ponadto odkrywanie powiązań pomiędzy mutacjami genetyczny-
mi a omawianą chorobą ma duże znaczenie dla pogłębiania wiedzy na temat prawidłowego funkcjonowania układu rozrodczego. 
(Endokrynol Pol 2013; 64 (4): 285–292)
Słowa kluczowe: hipogonadyzm, KAL1, GNRH1, GNRHR, PROK2, PROKR2, MLPA
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Introduction
Hypogonadism is defined as the failure in production 
of gonadal hormones, which may be due to lack of gon-
adotropin secretion (hypogonadotropic hypogonadism) 
or due to primary testicular failure (hypergonadotropic 
hypogonadism). The distinction between these disorders 
is made by the measurement of the serum concentrations 
of gonadotropins. IHH may be associated with anosmia 
or hyposmia (KS), or with a normal sense of smell (nIHH).
To date, several mutations have been identified as 
the underlying cause of the disease. However, they 
account for the molecular basis of less than 30% of 
all patients with IHH, which suggests that additional 
genes need to be discovered. These mutations can be 
divided into four groups: 1) those affecting GnRH neu-
ronal migration and functions; 2) those affecting GnRH 
synthesis and secretion; 3) those affecting hypophyseal 
response to GnRH; and 4) those affecting gonadotropin 
biosynthesis. Each of these steps is characterised by 
different phenotypic expressions.
The aim of the present study was to detect the 
prevalence of sequence variations of the KAL1, GNRH1, 
GNRHR, PROK2 and PROKR2 genes and to identify 
their role in the pathogenesis of the disease. Because it 
has several advantages over traditional screening meth-
ods, multiplex ligation dependent probe amplification 
(MLPA) was used to identify genomic rearrangements.
Material and methods
Patients and controls
86 hypogonadotropic hypogonadal men (76 with nIHH 
and ten with KS),  ages ranging from 19 to 25 years (21.70 
± 1.80 years [mean ± SD]) and 95 age-matched healthy 
eugonadal males of the same ethnic origin (21.68 ± 
2.13 years [mean ± SD]) were included in the study 
between May 2006 and October 2009 at the Department 
of Endocrinology and Metabolism, Gulhane School of 
Medicine, Ankara, Turkey.
Subjects with no history of recent or previously 
taken medication, aged over 18 (and bone age of < 18 
years), with symptoms and signs of hypogonadism 
(such as lack of libido, inability to have or maintain erec-
tion, Tanner stages 1 to 2), with subnormal testosterone 
levels and normal or reduced serum LH and FSH con-
centrations and those with normal karyotype (46, XY) 
served as the patient group. Subjects with constitutional 
delay of puberty or other hormonal imbalances were 
excluded from the study. All participants were tested 
with strong stimuli such as coffee, onion and garlic, and 
the patient group underwent MRI of the olfactory bulbs 
and tracts. Individuals with decreased sense of smell 
or anosmia were considered as having KS and those 
with normal sense of smell and with no evidence of 
morphological changes on the radiological examination 
were considered to have nIHH.
All patients and the control subjects were in-
formed about the aim and procedure of the study and 
written informed consent from all participants was 
obtained at the beginning. The study was approved 
by the ethics committee of the Gulhane School of 
Medicine.
Biochemical analysis
Blood samples withdrawn from a single vein at around 
8am after an overnight fast were collected into non-an-
ticoagulated tubes (Grainer, Australia) and centrifuged 
at 5,000 rpm for 10 minutes at room temperature. All 
serums were stored in the deep freeze at –80°C prior 
to use. Total T, FSH and LH levels were determined by 
a chemiluminescence immunoassay method using an 
automated immunoassay analyser (E170, Roche, Hitachi 
Corporation, Osaka, Japan) (Table I).
Genetic analysis
DNA was extracted from white blood cells of all patients 
and controls using BioRobot GenoVision Geno M-6 and 
EZ1 DNA Blood kit (Qiagen, Germany), according to 
the manufacturer’s instructions. A total of 125 ng DNA 
in 5 μL for each MLPA reaction was used. 
DNA denaturation
5 μL of DNA in 0.2 ml PCR-tubes were dissolved in TE 
(10 mM Tris-HCl pH 8.2 + 0.1 mM EDTA). The tubes 
were placed in a thermocycler and DNA samples were 
denatured for 5 minutes at 98°C and immediately cooled 
to 25°C before opening the thermocycler.
Table I. Hormonal profiles of the patients and control subjects 
Tabela I. Profile hormonalne pacjentów i osobników kontrolnych
Parameters Study Group (n = 86) Control Group (n = 95) p
Age (years) 21.70 ± 1.80 21.68 ± 2.13 0.75
Total testosterone [ng/dL] 65.11 ± 51.25 546.92 ± 131.12 < 0.001
FSH [mIU/mL] 0.80 ± 0.59 5.27 ± 2.07 < 0.001
LH [mIU/mL] 0.47 ± 0.55 5.31 ± 1.97 < 0.001
Data expressed as mean ± SD
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Hybridisation reaction
3 μL of a hybridisation master mix (1.5 μL MLPA buffer 
+ 1.5 μL probemix) was added to each sample tube and 
mixed well. The thermocycler programme was contin-
ued for 1 minute at 95°C, and then for 16 hours at 60°C.
Ligation reaction
A ligase master mix (3 μL Ligase-65 buffer A + 3 μL 
Ligase-65 buffer B + 25 μL dH2O) was prepared and 
mixed well by pipetting gently up and down. Then 1 μL 
of Ligase-65 was added and mixed again. Thermocycler 
was paused at 54°C and the 32 μL of the ligase master 
mix was added to each reaction tube. The programme 
was continued for 15 minutes at 54°C, followed by 
5 minutes at 98°C for heat inactivation of the Ligase-65 
enzyme and then paused at 15°C.
PCR reaction
A PCR buffer mix (4 μL SALSA PCR buffer + 26 μL 
dH2O) was prepared and mixed briefly by vortex-
ing. Then the 30 μL of PCR buffer mix was added to 
new tubes for the PCR reaction. 10 μL of each ligation 
product was transferred to its corresponding PCR tube 
at room temperature. A polymerase master mix (2 μL 
SALSA PCR-primers + 2 μL SALSA Enzyme dilution 
buffer + 5.5 μL dH2O + 0.5 μL SALSA Polymerase) was 
prepared and stored on ice until use. The thermocycler 
was heated to 60°C. The PCR tubes were placed in it 
and 10 μL polymerase mix was added to each tube. 
After mixing by pipetting gently up and down the ther-
mocycler programme was continued immediately. 35 
PCR cycles were run (30 seconds 95°C; 30 seconds 60°C; 
60 seconds 72°C) and ended with 20 minutes incubation 
at 72°C and then paused at 15°C.
Fragment separation
Following the PCR reaction, a mix (0.75 μL of the PCR 
reaction + 0.75 μL water + 0.5 μL size standard + 13.5 
μL HiDi formamide) was incubated for 2 minutes at 
94°C and stored on ice. PCR products were separated 
by capillary electrophoresis using a Beckman Coulter 
CEQ-8000 Genetic Analyser.
MLPA data analysis
Exonic deletions and duplications were examined by 
MLPA using commercial kits. The P132-Kallmann1 kit 
(MRC Holland, Amsterdam, Netherlands) contains 
MLPA probes for each of the 14 KAL1 exons, and the 
P133 Kallmann-2 kit contains (MRC Holland, Amster-
dam, Netherlands) MLPA probes for most exons of the 
FGFR1 gene (11 of the 18 exons), for some of the NELF 
(three of the 16 exons), GPR54 (three of the five exons), 
GNRH1 (three of the four exons), and for each of the 
GNRHR, PROK2 and PROKR2 genes.
Data was evaluated using Genotyper 2.0 (Applied 
Biosystems, Foster City, CA, USA). For analysis of the 
data, Coffalyser software (an Excel-based program) was 
used. Peak areas for each exon were converted into an 
Excel file and the relative DNA copy number ratios of 
each fragment were compared to the same fragments 
from two or three healthy subjects.
Statistical analysis
Statistical evaluation was performed using the Statis-
tical Package for the Social Sciences 15.0 (SPSS, Inc., 
Chicago, IL, USA). Parametric data was expressed as 
mean ± SD. The normality of distribution of continuous 
variables was evaluated using the Kolmogorov-Smirnov 
test. For between-group comparisons, if continuous 
variables were acceptable with normal distribution, we 
used Student’s t test; if not, we used the Mann-Whitney 
U test. A p-value of < 0.05 was considered statistically 
significant.
Results
Three patients with KS had deletions in exon 9 of the 
KAL1 gene (probe target sequence: 5941-L05940) and 
one of these patients had also a duplication in exon 11 
of the same gene (probe target sequence: 4427-L03813) 
(Figs. 1–3). Three patients with nIHH had a duplication 
in exon 3 of the PROK2 gene (probe target sequence: 
11953-L12773) (Fig. 4), a deletion in exon 2 of the GN-
RHR gene (probe target sequence: 4447-L05586) (Fig. 5), 
and a duplication in exon 1 of the GNRHR gene (probe 
target sequence: 4445-L03831) (Fig. 6), respectively. No 
deletions/duplications were identified in the GNRH1 
and PROKR2 genes in the patient group and none of 
the mentioned genomic rearrangements was detected 
in the control subjects.
In summary, using MLPA for the described genes, 
seven genomic rearrangements were present in 6/86 
(6.9%) patients with IHH. If only patients with nIHH 
were considered, 3/76 (3.9%) had previously described 
deletions or duplications; and if only KS patients were 
considered, 3/10 (30%) had KAL1 genomic rearrange-
ments, one of whom carried both deletion and duplica-
tion in the same gene (Table II).
When the genes were considered separately, 
genomic rearrangements in the KAL1, PROK2 and 
GNRHR were found in 3/86 (3.4%) (in 0/76 (0%) with 
nIHH and in 3/10 (30%) with KS), in 1/86 (1.1%) (in 1/76 
(1.3%) with nIHH and in 0/10 (0%) with KS), and in 2/86 
(2.3%) (in 2/76 (2.6%) with nIHH and in 0/10 (0%) with 
KS) hypogonadal patients, respectively.
All patients with KS were found to have some degree 
of high-arched palate and dental malocclusion, com-
pared to only a small minority of nIHH patients. These 
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Figure 1. Deletion in exon 9 of the KAL1 gene (probe target sequence: 5941-L05940)
Rycina 1. Delecja w egzonie 9 genu KAL1 (sekwencja docelowa sondy: 5941-L05940)
Figure 2. Deletion in exon 9 of the KAL1 gene (probe target sequence: 5941-L05940) and duplication in exon 11 of the same gene 
(probe target sequence: 4427-L03813)
Rycina 2. Delecja w egzonie 9 genu KAL1 (sekwencja docelowa sondy: 5941-L05940) i duplikacja w egzonie 11 tego samego genu 
(sekwencja docelowa sondy: 4427-L03813)
Figure 3. Deletion in exon 9 of the KAL1 gene (probe target sequence: 5941-L05940)
Rycina 3. Delecja w egzonie 9 genu KAL1 (sekwencja docelowa sondy: 5941-L05940)
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Figure 4. Duplication in exon 3 of the PROK2 gene (probe target sequence: 11953-L12773)
Rycina 4. Duplikacja w egzonie 3 genu PROK2 (sekwencja docelowa sondy: 11953-L12773)
Figure 5. Deletion in exon 2 of the GNRHR gene (probe target sequence: 4447-L05586)
Rycina 5. Delecja w egzonie 2 genu GNRHR (sekwencja docelowa sondy: 4447-L05586)
Figure 6. Duplication in exon 1 of the GNRHR gene (probe target sequence: 4445-L03831)
Rycina 6. Duplikacja w egzonie 1 genu GNRHR (sekwencja docelowa sondy: 4445-L03831)
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abnormalities were more profound in those with KAL1 
genomic rearrangements. No phenotypic abnormality 
was observed in the control group.
Discussion
In the present study we aimed to determine the preva-
lence of KAL1, PROK2, PROKR2, GNRH1 and GNRHR 
copy number variations in Turkish patients with IHH, 
using MLPA. The KAL1 gene is located on chromosome 
Xp22.3 and loss of KAL1 function is responsible for the 
X-linked form of the KS [1]. Mutations in the PROKR2 
and PROK2 genes, which are located on chromosomes 
20p12.3 and 3p13, are likely to be involved both in au-
tosomal recessive monogenic and digenic/oligogenic 
transmission modes [2]. The gene encoding GNRHR 
is located on chromosome 4q21.2 and mutations in 
the GnRHR are transmitted as an autosomal recessive 
trait. Although human GNRH1 gene mutations have 
not been reported yet, a gene located on chromosome 
8p21–11.2, loss of GNRH1 function was shown to be 
responsible for the autosomal recessive inheritance of 
IHH in an animal study [3].
İHH is a clinically and genetically heterogeneous 
disease, the genetic basis of which remains unknown 
in the majority of cases. It has been clinically classified 
into two major subgroups, KS and nIHH, depending 
on the presence or absence of a normal sense of smell. 
Patients with KS have either diminished (hyposmia) 
or absent (anosmia) sense of smell, in contrast to those 
with nIHH, whose sense of smell is normal [4]. As 
a result of their genetic heterogeneity, both disorders 
may occur as a part of various genetic defects. To date, 
several loss of function mutations in different genes 
have been described, resulting in recessive-X-linked, 
autosomal dominant and autosomal recessive modes 
of inheritance. These genetic causes account together 
for less than 30% [5], and much still remains to be 
discovered and understood regarding the underlying 
pathological processes. The underlying causes may 
be due to mutations involved in the multiple steps 
of normal reproduction, such as GnRH neuronal mi-
gration and function, GnRH synthesis and secretion, 
hypophyseal response to GnRH, and gonadotropin 
biosynthesis.
The KAL1 gene encodes anosmin-1, a neural cell 
adhesion molecule that modulates the migration of neu-
roendocrine GnRH cells from the olfactory epithelium 
to the hypothalamus during foetal development [6, 7]. 
Consequently, hypogonadism in KS is due to GnRH 
deficiency, which most probably results from a failure 
of this embryonic neuronal migration [8. 9], and the 
defective sense of smell is related to the hypoplasia or 
aplasia of the olfactory bulbs and tracts [10]. The KAL1 
gene was first reported as being defective in patients 
with KS by Franco et al. and Legouis et al. in 1991 [11, 
12], whereas Bick et al. identified the first intragenic 
deletion of the KAL1 gene in 1992 [13]. Different mu-
tations, widely distributed throughout the 14 exons of 
the gene, have been described in KS patients. However, 
these genetic defects have been discovered only in ap-
proximately 10% of KS patients [14]. The prevalence of 
KAL1 mutations in apparent sporadic forms of IHH, 
with or without anosmia, has been variably reported 
to range from 3.1% to 27.8% [15, 16]. Bhagavath et al. 
stated that the overall frequency of KAL1 mutations 
might not be as prevalent as previously estimated. The 
prevalence reported in 138 IHH patients (109 males and 
29 females) was 3.7% for male patients with nIHH and 
6.3% for male patients with KS, although no mutation 
was detected in females [17]. 
In the present study, three patients with IHH had 
a deletion in exon 9 of the KAL1 gene (probe target 
sequence: 5941-L05940) and one of these patients also 
carried a duplication in exon 11 of the same gene (probe 
target sequence: 4427-L03813). The prevalence of the 
Table II. Characteristics of genomic variations in the patient group
Tabela II. Charakterystyka zmienności genetycznych w grupie pacjentów
Patient No. Length (nt) SALSA MLPA probe Exon Ligation site Partial sequence (20 nt adjacent  
to ligation site)
Distance to 
next exon
29 229 5941-L05940 KAL1 exon 9 1434-1435 AACTTGCAGT-CTGGAAGTCG 14.4 kb
43 154 11953-L12773 PROK2 exon 3 Intron CCCAGAAGAA-TTAGCCTTTA 1.6 kb
65 283 4447-L05586 GNRHR exon 2 2415-2416 CTCTTCATCA-TCCCTCTTTT 4.0 kb
76 148 4445-L03831 GNRHR exon 1 426-427 ACTGGTCTAA-GCTGCTCAAG 1.6 kb
81 229
265
5941-L05940
4427-L03813
KAL1 exon 9
KAL1 exon 11
1434-1435
1737-1738
AACTTGCAGT-CTGGAAGTCG
TAAGGGGAAG-AGCCACAAGC
14.4 kb
2.9 kb
84 229 5941-L05940 KAL1 exon 9 1434-1435 AACTTGCAGT-CTGGAAGTCG 14.4 kb
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genomic rearrangements in the KAL1 was found to be 
3.4% among the patient group, which was consistent 
with the previous studies. When the nIHH and KS pa-
tients were considered separately it was 3.9% among 
the patients with nIHH and 30% among the patients 
with KS.
The best known smell identification test in the 
literature is The University of Pennsylvania Smell 
Identification Test (UPSIT) [18]. However, there are no 
standardised olfaction scores for the Turkish population. 
Clinical assessment of olfactory function in our study 
population was performed qualitatively by asking the 
subjects to identify strong odours such as coffee, onion, 
garlic etc. For more accurate diagnosis, the olfactory 
tracts and bulbs of each patient were also examined by 
MRI, which is the most preferred imaging technique 
for the evaluation of olfactory disorders. However, MRI 
scans of the olfactory pathways revealed no abnormal-
ity in the study population, including those with KS. 
On the other hand, craniofacial and dental anomalies, 
such as high-arched palate and malocclusion, were 
observed in all KS patients on physical examination, 
suggesting that KAL1 genomic rearrangements might 
be associated with more profound phenotypic conse-
quences. Human studies have shown that other midline 
craniofacial abnormalities (including cleft palate, cleft 
lip or choanal atresia), involuntary upper limb mirror 
movements (bimanual synkinesis), dental or renal 
agenesis, sensorineural deafness, oculomotor deficits, 
and other less documented developmental disorders 
may also occur in these patients [19].
It has been shown that the genes encoding ligand 
PROK2 and its related G protein-coupled receptor 
(PROKR2) are also essential for normal olfactory bulb 
and reproductive system development in mice [20] and 
in patients with IHH [21, 22]. Homozygous mutant mice, 
that do not exhibit this transmembrane receptor, show 
abnormal development of the olfactory bulb and severe 
atrophy of the reproductive system, but no significant 
abnormalities were observed in the heterozygous mice 
[23]. It has been reported that higher anosmin-1 levels 
in heterozygous mutant mice are protective from these 
developmental failures [24]. Mutations described within 
the PROK2/PROKR2 system account for less than 10% 
of subjects with KS and nIHH [21, 22]. In a large group of 
hypogonadal patients (170 with KS and 154 with nIHH), 
Cole et al. identified PROK2 gene mutations to cause KS 
and nIHH in 2% and less than 1% of cases, respectively. 
However, PROKR2 gene mutations were described in 
4% of KS patients and 3% of patients with nIHH [25]. 
Interestingly, cases presenting with mutations in both 
KAL1 and PROKR2 genes have been rarely reported, 
suggesting possible digenic inheritance in KS [10, 26]. 
In the present study, only one patient with nIHH had 
a duplication in exon 3 of the PROK2 gene (probe 
target sequence: 11953-L12773), and the prevalence 
was found to be 1.1% among the patient group, which 
was comparable with the previous data. However, no 
deletion or duplication was detected in the PROKR2 
gene. When the nIHH and KS patients were considered 
separately, it was 1.3% among the patients with nIHH 
and 0% among the patients with KS.
Mutations in the GNRHR gene were first defined 
by de Roux et al. in 1997 [27], and subsequently around 
20 different mutations have been reported in patients 
with sporadic or familial IHH [28]. The prevalence of 
GNRHR gene mutations was reported to account for 
40% in familial and 16.7% in sporadic nIHH cases [29]. 
Although they were shown to be responsible for hypo-
gonadotropic hypogonadism in animal studies, human 
studies failed to identify GNRH1 gene mutations. In the 
present study, two GNRHR gene deletions (one in exon 
2 (probe target sequence: 4447-L05586) and another 
in exon 1 (probe target sequence: 4445-L03831)) were 
identified in patients with nIHH. The prevalence of the 
genomic rearrangements in the GNRHR was found to 
be 2.3% among the patients with IHH, less common 
than the prevalence reported in the literature. No copy 
number variation was described in the GNRH1 gene. 
When considered independently, the percentage was 
2.6 among the patients with nIHH and 0% among the 
patients with KS.
Because the patients with the above-mentioned 
gene rearrangements in the present study had no family 
history of delayed sexual development, hypogonadism 
or defective smell sense, these genomic variations 
were thought to be sporadic in occurrence. However, 
previous familial history of affected individuals is also 
unlikely due to autosomal recessive inheritance of 
GNRH1, GNRHR, PROK2, PROKR2 and some forms 
of KAL1 gene mutations,
MLPA is a relatively new and effective technique 
for detecting deletions and duplications in genomic 
sequences [30]. To date, most of the prevalence studies 
have used PCR-based DNA sequencing in detecting 
point mutations and small deletions or duplications 
[31]. Amplification of the remaining normal allele 
makes this traditional technique unable to detect 
heterozygous gene deletions and duplications. Copy 
number variations that escape detection using current 
PCR-based techniques were found in patients with 
cystic fibrosis [32] and breast/ovarian cancer [33] using 
MLPA, suggesting that a considerable number of muta-
tions are likely to remain undiagnosed. However, gene 
deletions have been identified in an approximately 
similar percentage by MLPA, compared to previous 
studies using the traditional PCR-based sequencing 
methods [34].
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IHH is an important health problem and most cases 
are potentially treatable either with testosterone, or gon-
adotropin / GnRH replacement. However, correct clinical 
and genetic diagnosis of this condition is essential. Hence, 
analysis of genetic defects can help to confirm the clinical 
diagnosis and may also be a practical method for carrier 
detection, genetic counselling and prenatal diagnosis, 
particularly in families with no mutation. Because MLPA 
reaction is fast, cheap and very simple to perform, it may 
be more easily incorporated into clinical applications.
Conclusion
In recent years, several genes involved in the develop-
ment of hypothalamic-pituitary-gonadal axis have been 
identified. However, mutations in the prescribed genes 
account for a small minority of cases, signifying that oth-
er genes may be involved in the pathogenesis of IHH. 
Further studies of genes that regulate hypothalamic-
pituitary-gonadal development and functions should 
be carried out to clarify the additional genetic defects.
For detecting genomic deletions and duplications, 
MLPA has advantages over the traditional methods be-
cause of its simplicity, relatively low cost, and efficiency.
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